On Monday, Inozyme Pharma Inc (NASDAQ: INZY) was 2.95% up from the session before settling in for the closing price of $2.71. A 52-week range for INZY has been $2.56 – $7.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -16.46%. With a float of $43.50 million, this company’s outstanding shares have now reached $64.18 million.
Considering the fact that the conglomerate employs 59 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 55.92%, operating margin of -5043.98%, and the pretax margin is -4883.3%.
Inozyme Pharma Inc (INZY) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Inozyme Pharma Inc stocks. The insider ownership of Inozyme Pharma Inc is 32.28%, while institutional ownership is 63.25%. The most recent insider transaction that took place on Apr 02 ’24, was worth 52,210. In this transaction CEO of this company sold 7,523 shares at a rate of $6.94, taking the stock ownership to the 20,665 shares.
Inozyme Pharma Inc (INZY) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.35 earnings per share (EPS) during the time that was less than consensus figure (set at -0.31) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.10% during the next five years compared to -35.73% drop over the previous five years of trading.
Inozyme Pharma Inc (NASDAQ: INZY) Trading Performance Indicators
You can see what Inozyme Pharma Inc (INZY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.55, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Inozyme Pharma Inc (INZY)
Compared to the last year’s volume of 0.44 million, its volume of 1.42 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 33.55%. Additionally, its Average True Range was 0.25.
During the past 100 days, Inozyme Pharma Inc’s (INZY) raw stochastic average was set at 6.50%, which indicates a significant decrease from 16.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.28% in the past 14 days, which was higher than the 60.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.35, while its 200-day Moving Average is $5.01. Nevertheless, the first resistance level for the watch stands at $2.91 in the near term. At $3.03, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.21. If the price goes on to break the first support level at $2.61, it is likely to go to the next support level at $2.43. Should the price break the second support level, the third support level stands at $2.31.
Inozyme Pharma Inc (NASDAQ: INZY) Key Stats
There are 64,240K outstanding shares of the company, which has a market capitalization of 179.23 million. As of now, sales total 0 K while income totals -71,170 K. Its latest quarter income was 0 K while its last quarter net income were -24,570 K.
